Results 101 to 110 of about 115,566 (252)

Long‐term safety and efficacy of secukinumab in paediatric severe plaque psoriasis: 236‐week, Phase 3 trial results

Journal of the European Academy of Dermatology and Venereology, EarlyView.
In this Phase III study, secukinumab demonstrated sustained efficacy and a favourable safety profile in paediatric patients with chronic severe plaque psoriasis over a treatment period of 236 weeks. Abstract Background Plaque psoriasis, a chronic inflammatory disease, affects up to 2.1% of the global paediatric population.
Andrzej Kaszuba, Philemon Papanastasiou, Dorota Krasowska, Raul De Lucas Laguna, Michael Ziv, Shoba Ravichandran, Amita Bansal, Swapnil S. Dahale, Ruvie Martin, Bertrand Paguet, Nina Magnolo, Kulli Kingo   +11 more
wiley   +1 more source

Risk of candidiasis associated with interleukin-17 inhibitors: Implications and management

Mycology
The application of interleukin-17 (IL-17) inhibitors, including secukinumab, ixekizumab, brodalumab, and bimekizumab, are associated with elevated risk of candidiasis. These medications interfere with the IL-17 pathway, which is essential for maintaining
Hazrat Bilal, Muhammad Nadeem Khan, Sabir Khan, Wenjie Fang, Wenqiang Chang, Bin Yin, Ning-Jing Song, Zhongrong Liu, Dongxing Zhang, Fen Yao, Xun Wang, Qian Wang, Lin Cai, Bing Hou, Jiayue Wang, Chunyan Mao, Lingxi Liu, Yuebin Zeng   +17 more
doaj   +1 more source

Maternal pregnancy-induced hypertension increases the subsequent risk of neonatal candidiasis: A nationwide population-based cohort study

Taiwanese Journal of Obstetrics & Gynecology, 2019
Objective: Neonatal candidiasis is a leading infectious cause of significant morbidity and mortality in premature birth mainly due to impaired physical barriers and immature immune system of fetus.
San-Nung Chen, Peng-Hui Wang, Ming-Fang Hsieh, Hsiao-Wen Tsai, Li-Te Lin, Kuan-Hao Tsui   +5 more
doaj   +1 more source

Congenital candidiasis

Indian Dermatology Online Journal, 2014
Congenital candidiasis (CC) is a rare disease with less than 100 cases being reported in the literature. It presents within six days of life with manifestations ranging from localized skin disease to systemic involvement in the form of respiratory distress, sepsis, and death.
Chintaginjala Aruna, Kolalapudi Seetharam   +1 more
openaire   +3 more sources

Efficacy and safety of brodalumab in palmoplantar pustulosis: A 68‐week randomized Phase 3 trial

Journal of the European Academy of Dermatology and Venereology, EarlyView.
This open‐label study is a continuation of the 16‐week double‐blind, Phase 3 trial assessing the efficacy and safety of brodalumab 210 mg subcutaneously, till a 68‐week extension period. Continued improvement was seen in the PPPASI 50/75/90 responses, PPPSI scores, PGA 0/1 responses and DLQI. Abstract Background The efficacy and safety of brodalumab in
Masamoto Murakami, Yukari Okubo, Satomi Kobayashi, Natsuko Kikuta, Yoshiumi Ouchi, Kenta Shishido, Tadashi Terui   +6 more
wiley   +1 more source

Diversity and clinical presentation of Candida species in human immunodeficiency virus patients with oral candidiasis

Saudi Journal of Oral Sciences, 2019
Background: Change in the distribution profile of nonalbicans Candida species (spp.) can be an indication of immunosuppression or drug resistance to oral candidiasis in patients with human immunodeficiency virus (HIV).
Varun Nair, Arvind Shetti
doaj   +1 more source

Clinical features and risk factors for Sjogren’s syndrome patients suffering from oral candidiasis in Shanxi, China

BMC Oral Health
Objectives To investigate the clinical features and risk factors of Sjogren’s Syndrome (SS) patients suffering from oral candidiasis and to provide a foundation for the prevention and treatment of oral candidiasis in SS patients.
Yexing Xing, Honghong Shi, Caihong Wang, Ying Yang   +3 more
doaj   +1 more source

Current treatment of oral candidiasis: a literature review [PDF]

, 2014
Candidiasis or oral candidosis is one of the most common human opportunistic fungal infections of the oral cavity. This pathology has a wide variety of treatment which has been studied until these days. The present study offers a literature review on the
Bagán Sebastián, José Vicente, Garcia Cuesta, Carla, Sarrión Pérez, María Gracia   +2 more
core   +2 more sources

French guidelines on systemic treatments for moderate‐to‐severe psoriasis in adults: Update 2025

Journal of the European Academy of Dermatology and Venereology, EarlyView.
New 2025 French guidelines update psoriasis management with revised algorithms integrating recent systemic therapies. They recommend methotrexate, adalimumab or ustekinumab as first‐line treatments and provide guidance for special psoriasis forms, comorbidities, pregnancy and long‐term management.
Marie Masson Regnault, Emilie Brenaut, Marie‐Emeline Marniquet, Carla Berthault, Lea Canoen, Clarisse Marcombes, Audrey Melin, Raphaël Ouakrat, Julie Charles, Stephane Mouret, Olivier Potie, Laetitia Penso, Laura Pina Vegas, Guillaume Larid, Marine Roux, Colombe Bougeard, Sandy Sylvain, Clara Labonne, Tania Randriamiarana, Da Hee Pitaud, Floriane Etheve, Jeremy Gottlieb, Laurie Gouillon, Marine Chastagner, Emilie Sbidian, Hélène Aubert, on behalf of the Psoriasis Research Group of the French Society of Dermatology (Groupe de Recherche sur le Psoriasis de la Société Française de Dermatologie), Hélène Aubert, Marie Masson Regnault, Emilie Brenaut, Emilie Sbidian, Laura Pina Vegas, Laetitia Penso, Jeremy Gottlieb, Marine Roux, Clara Labonne, Tania Randriamiarana, Floriane Etheve, Da Hee Pitaud, Marie‐Emeline Marniquet, Carla Berthault, Clarisse Marcombes, Audrey Melin, Colombe Bougeard, Julie Charles, Olivier Potie, Léa Canoen, Laurie Gouillon, Marine Chastagner, Sandy Sylvain, Guillaume Larid, Raphaël Ouakrat   +51 more
wiley   +1 more source

Rational treatment for vulvovaginal candidiasis caused by resistant Candida species [PDF]

РМЖ. Мать и дитя, 2019
G.B. Dikke F.I. Inozemtsev Academy of Medical Education, St. Petersburg, Russian Federation In recent decade, growing incidence (24–29%) of vulvovaginal candidiasis caused by Candida non-albicans is reported.
G.B. Dikke
doaj